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Abstract 
Melioidosis caused by gram negative bacteria, B. pseudomallei, is a fatal disease in the tropical and sub-tropical 
regions. However, sporadic cases have been reported in elsewhere. Early detection is imperative to reduce the mortal-
ity rate. Serological tests have being substantially developed using recombinant proteins as specific targeted antigens 
to melioidosis antibodies. In the present study, we focus on a truncated flagellin fragment (FLAG300) and outer mem-
brane protein A (OmpABT) of B. thailandensis E264 as potential antigens for developing indirect ELISA to improve the 
serodiagnosis of melioidosis. Recombinant proteins were overexpressed and purified by immobilized metal affinity 
chromatography with denaturing conditions. The sensitivity and specificity of individual test were calculated within 
culture-confirmed melioidosis sera (n = 42) and non-melioidosis serum samples (n = 241) using the cut-off point 
at average of absorbance plus 2 standard deviations. The results demonstrated that a FLAG 300 based indirect ELISA 
showed 90.48 % sensitivity and 87.14 % specificity and an OmpABT based this assay revealed sensitivity of 80.95 % 
and specificity of 89.21 %. Their use in a double-antigen ELISA resulted in improve specificity (92.95 %) and still high 
degree of sensitivity (85.71 %). These data suggest a facile method for serodiagnosis of melioidosis by the use of anti-
gens from a non-pathogenic strain.
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Background
Burkholderia pseudomallei infection, melioidosis, is 
an infectious disease that is mainly described in the 
major endemic areas of SE Asia and Northern Aus-
tralia. However, there have been reported cases out-
side these endemic regions such as in Brasil, India and 
United States of America (Corral et al. 2008; Deshmukh 
and Mundhada 2013; Kunnathuparambil et  al. 2013; 
Miralles et  al. 2004). It is a major public health prob-
lem in Southeast Asia and Northern Australia (Dance 
1991; Leelarasamee and Bovornkitti 1989), because the 
mortality rate is still high even with treatment, and no 
effective vaccine is available so far. The clinical manifes-
tations of this disease are diverse, ranging from chronic 
localized infection in many organs to acute septicemia, 
complicating the clinical diagnosis of melioidosis. In 
septicemic cases, expiration will occur in a few days; 
thus reliable and early diagnosis is imperative. Although 
bacterial isolation and identification is the defini-
tive diagnostic method, it is a time consuming strategy 
(5–7 days) (Cheng 2010). Moreover, bacterial culture is 
an imperfect reference method because it has low sen-
sitivity and negative predictive value (Limmathurot-
sakul et al. 2010). Serological diagnosis of melioidosis is 
widely used in endemic regions, especially the indirect 
hemagglutination assay (IHA); however, it has limited 
utility for diagnosis because of relatively poor sensitivity 
(Appassakij et al. 1990; Harris et al. 2009; Sorenson et al. 
2013) and a high seropositivity background in endemic 
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areas (Ashdown and Guard 1984; Kanaphun et al. 1993). 
Although it is of limited value for diagnosis in those 
areas, it may be of assistance in some circumstances, 
particularly when paired sera are available or high serum 
titers are reported with the presence of clinical signs. 
Currently, a number of serodiagnostic tests for melioi-
dosis detection has been developed using crude extracts 
(Sorenson et  al. 2013; Cooper et  al. 2013; Parthasar-
athy et al. 2006) or purified recombinant proteins from 
B. pseudomallei (Allwood et al. 2008; Arora et al. 2015; 
Chantratita et  al. 2007; Chen et  al. 2003; Druar et  al. 
2008) as antigens. Even though they obviously demon-
strate substantial improvement over the clinical stand-
ard IHA test, all antigens are derived from a Tier 1 agent, 
B. pseudomallei, and thus manipulations must be done 
under biosafety level 3 (BSL-3). Conversely, such experi-
ments with a close relative of this bacterium, B. thai-
landensis, can dispense with this biosafety level (Rotz 
et  al. 2002). Both of the organisms are broadly similar 
genetically and immunologically (Yu et al. 2006). Previ-
ous studies indicate that melioidosis protective antibod-
ies can be raised using antigens from B. thailandensis 
(Ngugi et  al. 2010; Scott et  al. 2013) and certain anti-
gens of B. pseudomallei share epitopes with this closely 
related species (Wajanarogana et  al. 2013). In addition, 
some biological properties of B. pseudomallei have been 
explained by using B. thailandensis as a non-pathogenic 
model (Haraga et al. 2008).
A number of serodiagnostic antigens of B. pseudomal-
lei have been revealed using protein microarray (Felgner 
et al. 2009) and indirect enzyme-linked immunosorbent 
assays (ELISA) (Allwood et  al. 2008; Arora et  al. 2015; 
Wajanarogana et  al. 2013; Hara et  al. 2013). The major-
ity of such antigens are cell surface-associated proteins 
such as outer membrane proteins (Omps), and secreted 
molecules. In this study, we focused on Omps, especially 
outer membrane protein A (OmpA) and truncated flagel-
lin fragment (FLAG300) of B. thailandensis E264. The 
FLAG300 indicates as the potential antigen for diagnosis 
of melioidosis (Wajanarogana et al. 2013); however, cul-
ture-confirmed melioidosis serum samples have not yet 
been studied. As well as a flagellin fragment, OmpA of 
B. pseudomallei has immunogenic properties which has 
been used for serodiagnosis of melioidosis (Allwood et al. 
2008; Arora et al. 2015; Hara et al. 2013). Moreover, both 
of these antigens have been suggested as potential can-
didate vaccines (Brett and Woods 1996; Hara et al. 2009; 
Ye and Gan 2007). Our preliminary study has found that 
ompA sequences of B. pseudomallei and closely related 
species show high homologues. Here, we isolate ompA 
from B. thailandensis E264 and express and purify it as 
recombinant protein for developing serodiagnosis of 
melioidosis, together with FLAG300.
Methods
Bacterial strains, cloning vector and culture condition
The OmpA gene and the truncated of flagellin gene of B. 
thailandensis E264 were inserted into expression vector, 
pET-24a(+) (Novagen). E. coli BL21(DE3) and XL1-Blue 
harboring recombinant expression vectors were basically 
grown in Luria–Bertani (LB) medium containing kana-
mycin (50 µg ml−1) at 37 °C with shaking.
Serum specimens
Sera were used in this study from the following three 
groups of individuals: (1) Culture confirmed-positive 
of melioidosis serum samples collected from endemic 
regions, Amnat Charoen hospital and Khon Khaen hos-
pital, Thailand (n  =  42). (2) Serum samples from sep-
ticemic patients caused by other infectious bacteria (i.e. 
Klebsiella pneumoniae, Escherichia coli, Pseudomonas 
aeruginosa, gram positive bacteria and gram negative 
non-fermenter bacteria) (n =  74) collected from Tham-
masat hospital, Thailand. This group was used as the 
disease control. (3) Normal sera collected from healthy 
blood donor served as the negative control group 
(n = 167). The last group was obtained from Thammasat 
hospital (n = 49) and Amnat Charoen hospital (n = 118), 
Thailand. All sera in this study are leftover specimens 
of routine laboratory without direct contact with the 
patients and personal data record. Collection of serum 
samples was approved by the Rangsit University Ethics 
Committee (No. RSEC 17/35).
OmpA gene isolation and cloning
The nucleotides sequence of ompA (BPSL2522; Sanger 
Research Institute, http://www.sanger.ac.uk) was used 
to design oligonucleotide primers to amplify ompA 
from B. thailandensis E264 with incorporated restric-
tion sites. Forward primer, OmpAF (5′-CGCATATG 
AATAAACTTTCAAAGCTC-3′) and reverse primer, 
OmpAR (5′-GAATTCGCCTTCGCCG GAACG-3′), that 
introduced NdeI and EcoRI endonuclease sites (under-
lined), respectively, were custom synthesized from Bio 
Basic Inc., Canada. The polymerase chain reaction (PCR) 
was carried out with 100–200  ng of DNA template, 
20 pmol of each primer, 1× Pfu buffer with MgSO4, 0.5 µl 
of 20  mM dNTPs, and 1.25 U of Pfu DNA polymerase 
(Fermentas, Life Sciences). Prior to DNA amplification, 
the mixture was heated at 99  °C for 5  min. The condi-
tions for PCR amplification were as follows: one cycle 
of denaturation at 95  °C for 5  min, annealing at 60  °C 
for 1 min and extension at 72 °C for 1 min, 34 cycles of 
denaturation at 95  °C for 1  min, annealing and exten-
sion as the same previous condition, and the final cycle 
at 72  °C for 5 min. The PCR product was digested with 
NdeI plus EcoRI (Biolab) and cloned as an NdeI-EcoRI 
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fragment downstream of the T7 promoter in the expres-
sion vector, pET24a(+), designated pET24a-OmpABT. 
The BL21(DE3) strain was transformed with pET24a-
OmpABT recombinant plasmids.
DNA sequencing and analysis
The nucleotides sequence of the selected clone was cus-
tom carried out in both orientations by Ward Medic Ltd. 
Part, Thailand. The sequence was analyzed by searching 
for homology in the entire database by nucleotide type of 
similarity search (blastn) with the BLAST program (Alts-
chul et  al. 1997) at the NCBI server (http://www.ncbi.
nlm.nih.gov/BLAST/) and compared with the OmpA 
sequence (BPSL2522) of B. pseudomallei (www.ebi.ac.th).
Recombinant proteins expression and purification
A successful transformant, E. coli BL21(DE3) contain-
ing pET24a-OmpABT, was grown overnight in a 5  ml 
LB broth containing 50 µg ml−1 kanamycin at 37 °C with 
shaking. The overnight culture was used to inoculate 
200 ml fresh LB broth (50 µg ml−1 kanamycin) at 1:100 
dilution and cultured at 37 °C to an OD600nm of 0.6–0.8. 
Isopropyl-β-d-thiogalactoside (IPTG; Fermentas, Life 
Sciences) was added to the final concentration of 1 mM 
to induce protein expression. The induced culture was 
allowed to grow for 2 h at 37 °C with shaking at 200 rpm 
before the cells were harvested by centrifugation at 
6000  rpm for 10  min at 4  °C. The cell pellet was resus-
pended in 5 ml of lysis buffer (IMAC5 pH 8.0) containing 
20 mM Na2HPO4, 1 M NaCl, 10 % (v/v) glycerol, 5 mM 
imidazole and 15 µl of protease inhibitor cocktail (Roche 
applied Science) and lysed by sonication. After cell dis-
ruption, the resulting preparation was separated into 
soluble and insoluble or inclusion body fractions by cen-
trifugation at 13,000 rpm for 30 min at 4 °C. The inclusion 
body was solubilized in IMAC5 containing 8 M urea and 
5 mM dithiothreitol (DTT) overnight at room tempera-
ture under orbital agitation. Any insoluble materials were 
removed by centrifugation at 13,000 rpm for 60 min. The 
solubilized inclusion body was purified by IMAC under 
denaturing conditions using TALON® metal affinity res-
ins (Clontech Laboratories Inc.). The equilibrated resins 
were incubated with the solubilized inclusion body for 
3–4  h at room temperature under orbital agitation and 
then were loaded on a column. The column was continu-
ously washed with 20 column volume (CV) of equilibra-
tion solution, 10 CV of IMAC10 (20 mM Na2HPO4, 1 M 
NaCl, 10  % (v/v) glycerol, 8  M urea and 10  mM imida-
zole), 10 CV of IMAC15 (20 mM Na2HPO4, 1 M NaCl, 
10 % (v/v) glycerol, 8 M urea and 15 mM imidazole) and 
the final step with 10 CV of IMAC20 (20 mM Na2HPO4, 
1  M NaCl, 10  % (v/v) glycerol, 8  M urea and 20  mM 
imidazole). The bound protein was eluted with 5 CV of 
20 mM Na2HPO4, 1 M NaCl, 10 % (v/v) glycerol, 400 mM 
imidazole, 8 M urea, and 5 mM DTT. The elution fraction 
was concentrated using Amicon® Ultra centrifugal filter 
(Millpore Corporation). The protein concentration was 
determined by Bradford protein assay (Bio-Rad Labora-
tories Inc.). The truncated flagellin protein (FLAG300) 
was expressed and purified as describe in the previous 
report (Wajanarogana et al. 2013).
SDS‑PAGE and western blot analysis
The expressed and purified proteins were analyzed by 
SDS-PAGE according to the method described by Lae-
mmli (1970) with 12  % polyacrylamide gel. After pro-
teins were separated on the gels by electrophoresis, 
they were stained with Coomassie brilliant blue R-250 
or electrophoretically transferred onto a polyvinylidene 
difluoride (PVDF) membrane (Pall Corporation) using 
Trans-blot®SD semi-dry transfer cell (Bio-Rad Laborato-
ries Inc.). The blotted membrane was washed twice with 
TBS buffer (10 mM Tris–HCl pH 7.5, 150 mM NaCl) and 
blocked with blocking buffer (0.25 g blocking reagent in 
50 ml of blocking reagent buffer, QIAexpress® detection 
assay) for 1 h at room temperature. After twice washing 
with TBST (20  mM Trish HCl pH 7.5, 500  mM NaCl, 
0.05  % (v/v) Tween 20 and 0.2  % (v/v) Triton X-100), 
1:1000 diluted anti-his HRP conjugate in blocking buffer 
was added and incubated for 1 h. Prior to protein band 
detection, the membrane was washed twice with TBST 
and one time with TBS buffer. Immunoreactive protein 
band was visualized with 3,3′,5,5′-tetramethylbenzidine 
(TMB) (KPL).
Indirect ELISA and its evaluation
Prior to evaluate the potential of recombinant proteins 
as antigens for serodiagnosis of melioidosis with indirect 
ELISA, the optimal concentration of this assay reagents 
was determined by checkerboard titration method using 
pooled of five culture confirmed-positive of melioidosis 
sera and five sera of healthy donors. It was performed in 
duplicate using Microlon® plates (Greiner bio-one). The 
96-well microtiter plates were separately coated with 
100  µl of 0.1  µg  ml−1 of recombinant OmpABT puri-
fied protein antigen and 100 µl of 1 µg ml−1 of purified 
truncated flagellin fragment in coating buffer (carbon-
ate/bicarbonate buffer, pH 9.6) at 4  °C for overnight. 
The plates were blocked with 150  µl of blocking buffer 
(0.5  % of bovine serum albumin in coating buffer) at 
37  °C for 1  h and they were washed 3 times with PBS-
Tween solution [PBS and 0.05 % (v/v) Tween 20)]. After 
washing, 100 µl of diluted serum samples (1:3200) in PBS 
were added in each well and then the plates were further 
incubated at room temperature for 1  h. The wells were 
washed with PBS-Tween solution 3 times and added 
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with 100  µl of diluted (1:1000) anti-human IgG conju-
gated with HRP (KPL). After 1 h incubation at 37 °C, the 
wells were washed with PBS-Tween solution 3 times and 
100  µl of TMB substrate solutions were added to each 
well. The reaction was left to develop for 15  min and 
stopped with 100  µl of 1  N HCl. The reaction products 
were determined using a microplate reader at OD450nm 
(Bio-Rad model 550; Bio-Rad Laboratories Inc.). On each 
plate, combinations of positive (pooled positive) and neg-
ative controls (direct conjugate control) were carried out 
in duplicate.
Data analysis
The mean and standard deviation of normal serum sam-
ples were calculated and cut-off value was determined 
as the mean of normal controls plus two standard devia-
tions (SD). Serum samples were considered positive if the 
mean optical densities were higher than cut-off point. For 
consideration as positive following the criteria of multi-
ple-antigen ELISA, the serum tested specifically react 
with any antigen when the cut-off value was calculated 
from the mean optical densities plus three standard devi-
ations (Zhang et  al. 2009). Statistical analysis was per-
formed with GraphPad Prism version 5.0.
Results
OmpA gene cloning and DNA sequencing
The amplified product, 680 bps, was isolated from 
genomic DNA of B. thailandensis E264 by specific 
primers designed based on the ompA sequence of B. 
pseudomallei K96243. The purified amplicon was suc-
cessively digested with NdeI and EcoRI and cloned into 
NdeI/EcoRI linearized pET24a(+) to construct the 
recombinant plasmid (pET24a-OmpABT). After trans-
formation into E. coli BL21(DE3), a clone was selected to 
sequence and analyze. The nucleotide sequence showed 
a high degree of identity (98–100 %) to the OmpA fam-
ily protein of B. thailandensis and B. pseudomallei when 
examined by blastn (data not shown). A comparison 
of deduced amino acids sequence with the published 
OmpA protein of B. pseudomallei (BPSL 2522) revealed 
that they have about 99  % homology over the entire 
sequences (Fig. 1).
Analysis of expressed recombinant protein
The selected clone carrying the construct pET24a-
OmpABT plasmid was induced with 1  mM IPTG for 
2  h at 37  °C. The expressed proteins of about 27 and 
35  kDa appeared in the total cellular proteins as dem-
onstrated by SDS-PAGE analysis; however, they mainly 
resided within inclusion bodies (Fig.  2a). The iden-
tity of the expressed protein was confirmed by West-
ern blot analysis using anti-his antibody (Fig.  2b). The 
lower immune-reactive bands (less than 25  kDa) were 
observed and a less abundant higher molecular weight 
band (about 60 kDa) suggests that they present an inter-
nal degradation and a dimer of recombinant proteins 
(Allwood et al. 2008; Hara et al. 2009), respectively. Prior 
to protein purification under denaturing condition, the 
inclusion bodies was initially solubilized with 8 M urea 
and reduced with DTT and then insoluble material was 
removed by centrifugation. The soluble fraction was 
purified by Talon™ resins directed to the hexa-histidine 
tag at the carboxyl terminus of the recombinant pro-
tein based on immobilized metal affinity chromatogra-
phy (IMAC). Step-wise washing not only helped to get 
rid of non specific proteins but the targeted proteins 
were also lost (data not shown). The bound proteins 
were eluted with elution buffer and concentrated for use 
in the further step (Fig.  2). Purified recombinant pro-
tein was found to be 3.65 mg from 200 ml of culture or 
18.25 mg l−1.
Evaluation of constructed OmpABT and FLAG300 proteins 
as serodiagnostic reagents using indirect ELISA
Both recombinant antigens were used in this assay to 
detect antigen-specific IgG antibody in three groups 
of sera: bacterial culture confirmed-melioidosis sera, 
septicemia with other bacteria serum samples (dis-
eases control) and sera of blood donors from endemic 
areas (Amnat Charoen and Khon Khaen provinces) and 
non-endemic region (Pathumthani province). The opti-
mal cut-off point of individual recombinant antigens 
(mean plus two standard deviations) were calculated 
from absorbance values of serum samples from healthy 
donors (n =  167). They were found out to be 0.207037 
and 0.207312 for OmpABT and FLAG300, respectively. 
The average of optical densities (ODs) of endemic and 
non-endemic serum samples are not significantly differ-
ent. The OD values observed with of all the 3 sera groups 
and cut-off values are given in Fig. 3. The OD value of a 
serum sample greater than the cut-off point was consid-
ered as positive. The serodiagnostic indices of indirect 
ELISA using individual antigens based on defining the 
culture confirmed-positive sera and healthy donor and 
disease control sera as true positive and true negative, 
respectively were calculated (Table  1). The sensitivity 
of FLAG300 B. thailandensis was higher (90.48  %) than 
OmpABT (80.95  %) recombinant protein whereas the 
specificity was very similar (87.14 and 89.21 %) as well as 
the accuracy (around 88 %). Using a combination of two 
recombinant proteins to predict the potential for serodi-
agnosis of melioidosis, based on analysis of the individual 
reactivities of FLAG300 and OmpABT with the serum 
samples, was 85.71  % sensitivity and good specificity 
(92.95 %).
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Discussion
The diagnosis of melioidosis can be done within 3 strate-
gies, bacteriological, molecular and serological methods. 
Even though bacterial culture is the reference method so 
far, it has many limitations such as it is time consuming, 
requires good practice and a high level of experience of 
the investigator, and it is a relatively low sensitivity assay 
(Limmathurotsakul et  al. 2010). Septicemic melioidosis 
patients might expire before a laboratory report, and thus 
early detection is imperative. A number of serological 
tests being developed to improve diagnosis of melioido-
sis using both recombinant proteins and extracted anti-
gens from B. pseudomallei (Allwood et al. 2008; Anandan 
et al. 2010; Parthasarathy et al. 2008). In previous reports, 
the principal immunogenic proteins of B. pseudomallei 
are located on the cell surface such as OmpA or Omp3, 
truncated flagellin proteins and type IV pilus protein 
(PilO) (Allwood et  al. 2008; Chen et  al. 2003; Essex-
Lopresti et al. 2005). However, such reports reveal quite 
high diagnostic indices, and serious biosafety level con-
tainment facilities (BSL-3) are necessitated to develop 
such assays. Our previous report demonstrated that the 
flagellin protein fragment of the closely related species, B. 
thailandensis, can react with antibodies in positive sero-
diagnostic sera of melioidosis (Wajanarogana et al. 2013). 
Moreover, non-pathogenic B. thailandensis was used as 
a potential model to refer certain biological properties 
of B. pseudomallei because they are highly similar at the 
genetic level (Yu et al. 2006). The experimental manipu-
lation of non-pathogenic strain can be performed under 
standard routine microbiological condition (BSL-1). 
In the present study, we produced recombinant pro-
teins, OmpABT and FLAG300 in order to evaluate their 
potential as antigens for diagnosis of melioidosis by an 
indirect ELISA. The recombinant proteins were overex-
pressed as incorrectly folded insoluble products (Lilie 
et al. 1998). The expressed OmpABT does not require a 
refolding process, however, since there is recognition of 
linear epitopes. The recombinant proteins fused to hexa-
histidine tag at the carboxyl termini were single step 
purified under denaturing conditions with metal affinity 
resin chromatography. Although stringent washing con-
ditions were carried out, multiple protein bands were 
detected. However, those bands strongly react with anti-
hexa-histidine antibody indicating that they correspond 
to the fusion protein. The distinct bands with higher and 
slightly lower molecular weight than targeted recombi-
nant protein might be the results of different isoforms 
and proteolytic breakdown, respectively (Allwood et  al. 
2008; Hara et al. 2009).
Several previous studies demonstrate that truncated 
flagellin fragment and OmpA protein of B. pseudomallei 
serve as the diagnostic potential of melioidosis (Allwood 
et al. 2008; Arora et al. 2015; Chen et al. 2003; Hara et al. 
OmpABT      MNKLSKLAFIAATAVMAASASAQSVPASRQAVNDNWVNGTGEWVWMNGTNELCWRDAFWT 
BPSL2522           MNKLSKLAFIAATAVMAASASAQSVPASRQAVNDNWVNGTGEWVWMNGTNELCWRDAFWT 
************************************************************
OmpABT      PATANAKCDGALVAQAPAPAPVAPVAPAITSQKITYQADTLFDFDKAILKPAGKQKLDEL 
BPSL2522     PATANAKCDGALVAQAPAPAPVAPVAPAITSQKITYQADTLFDFDKAVLKPAGKQKLDEL 
***********************************************:************
OmpABT      AAKIQGMNVEVVVATGYTDRIGSDKYNDRLSLRRAQAVKSYLVSKGVPANKVYTEGKGKR 
BPSL2522           AAKIQGMNVEVVVATGYTDRIGSDKYNDRLSLRRAQAVKSYLVSKGVPANKVYTEGKGKR 
************************************************************
OmpABT     NPITGNTCKQKNRKQLIACLAPDRRVEVEVVGTQEVQKTTVPAKA 
BPSL2522           NPVTGNTCKQKNRKQLIACLAPDRRVEVEVVGTQEVQKTTVPAQ-
**:****************************************: 
Fig. 1 A comparison of deduced amino acid of OmpABT and the published OmpA protein of B. pseudomallei, BPSL 2522, asterisks represent identity 
and dots indicate similarity
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2013). In this study, the recombinant proteins, OmpABT 
and FLAG300, from the closely related species, B. thai-
landensis, were evaluated as antigens which specifically 
react to melioidosis antibodies using indirect ELISA and 
we calculated the serodiagnostic indices. The evaluations 
were performed with 42 culture confirmed-melioidosis 
sera, 74 other diseases control sera and 167 healthy donor 
sera. It is not surprising that the average absorbance of 
the two recombinant proteins was significantly higher in 
melioidosis patients sera compared to non-melioidosis 
sera (data not shown). The sensitivity (90.48 %) of ELISA 
with FLAG300 was found to be higher compared to a 
previous report (82.7  %) whilst the specificity (87.14  %) 
was slightly lower (94.6  %) (Wajanarogana et  al. 2013). 
The previous study used clinically suspected melioidosis 
sera with serological positive as a reference samples but 
in this work we used bacterial culture-confirmed sera. 
Moreover, the numbers of normal serum samples were 
quite different (40 and 167 samples). An ELISA using the 
Fig. 2 The expressed and purified OmpABT was confirmed by 12 % 
SDS-PAGE (a) and western blotting (b). Lanes 1 and 2, total cell lysate 
of E. coli harboring pET24a-OmpABT of uninduced and induced clone 
with IPTG, respectively, Lane 3, soluble fraction, Lane 4, inclusion bod-
ies fraction, Lane 5, concentrated eluted protein and Lane M, protein 
molecular weight marker. Relative molecular mass (kDa) of standard 
proteins is shown on the left-hand side. The arrowhead indicates the 





















































Fig. 3 The reactivity of serum samples with OmpABT (a) and 
FLAG300 antigens (b) in indirect ELISA. Both antigens were screened 
with culture confirmed-melioidosis sera (1), disease control sera 
(2) and healthy donor sera (3). Each symbol represents the average 
of duplicate readings of one serum samples. Cut-off values were 
showed by solid lines and mean of each group (dash lines)
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truncated flagellin antigen has been considered in non 
endemic area by Chen et al. (2003), which demonstrated 
high sensitivity (93.8 %) and specificity (96.3 %).
Various studies revealed a sensitivity of ELISA with 
recombinant OmpA antigen from B. pseudomallei 
between 59–95 and 90–98 % specificity, which were con-
sidered at various cut-off points (Allwood et  al. 2008; 
Arora et al. 2015; Hara et al. 2013). In this study, firstly, 
we detail the use of recombinant OmpA of B. thailan-
densis (OmpABT) as the potential antigen for diagnos-
tic of melioidosis by developing indirect ELISA. At the 
cut-off value (mean plus 2SD), good sensitivity (80.95 %) 
and specificity (89.21 %) were gained which substantially 
improved over the clinical standard indirect hemag-
glutination test (IHA). Because the carboxyl-termini 
of OmpAs are quite conserved within enteric bacteria 
and B. pseudomallei and contain the immunodominant 
epitope that is recognized by antibodies formed during 
the course of infections (Hara et  al. 2009; Jeannin et  al. 
2002; Puohiniemi et  al. 1990), infection with these bac-
teria raises antibody which cross react with OmpABT 
protein causing reduced specificity. The variable region 
of recombinant protein could be utilized to increase 
the specificity of the test although sensitivity might be 
reduced.
A novel approach using more than a single antigen to 
improve serodiagnosis of melioidosis has revealed that 
sensitivity is improved whilst retaining good specificity 
(Hara et  al. 2013). In this study we demonstrate better 
sensitivity (85.71 %) than OmpABT alone and improved 
specificity compared to either alone (92.95  %). Besides 
their utility in the diagnosis of melioidosis, these recom-
binant antigens should also be considered in the design of 
a vaccine against B. pseudomallei infection as they induce 
an immune response (Allwood et  al. 2008; Hara et  al. 
2009; Ye and Gan 2007).
Conclusion
Here, we suggest that the potential antigens of non-path-
ogenic B. thailandensis could be utilized to develop sero-
diagnosis of melioidosis within a single protein antigen or 
double antigens ELISA to eliminate health risks to labo-
ratory personnel for Tier-1 agent exposure.
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